Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 179.78M P/E - EPS this Y 26.10% Ern Qtrly Grth -
Income -80.55M Forward P/E -1.88 EPS next Y -5.80% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 50.00%
Dividend N/A Price/Book 1.30 EPS next 5Y - 52W High Chg -49.00%
Recommedations 1.60 Quick Ratio 6.67 Shares Outstanding 56.50M 52W Low Chg 196.00%
Insider Own 2.27% ROA -40.41% Shares Float 44.48M Beta 2.49
Inst Own 95.24% ROE -83.38% Shares Shorted/Prior 5.86M/6.01M Price 3.49
Gross Margin - Profit Margin - Avg. Volume 4,257,912 Target Price 14.83
Oper. Margin - Earnings Date Nov 4 Volume 369,175 Change -5.68%
About Black Diamond Therapeutics, Inc

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc News
11/05/24 Black Diamond: Q3 Earnings Snapshot
11/05/24 Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
11/05/24 Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/01/24 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
10/07/24 Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
09/23/24 Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
09/23/24 Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
09/22/24 Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
09/14/24 Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
08/08/24 Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08/08/24 All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
08/06/24 Black Diamond: Q2 Earnings Snapshot
08/06/24 Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/02/24 Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
06/29/24 Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?
06/01/24 Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
05/29/24 Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
05/22/24 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company
05/10/24 Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
05/09/24 Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
BDTX Chatroom

User Image 100K2022 Posted - 7 hours ago

$BDTX looks like new 52 week low coming in

User Image 100K2022 Posted - 8 hours ago

$BDTX don’t know how much more I can take. Haven’t seen green in days

User Image NYC_cartoon Posted - 15 hours ago

$BDTX Seems the price will back to $1, no big daily trade happen

User Image jpurvis Posted - 1 day ago

$TNYA Also good entry points in similar stocks like $BDTX and $RANI

User Image jpurvis Posted - 1 day ago

$BDTX Jumping in at $2.41

User Image Wilder992001 Posted - 1 day ago

$BDTX Hammer on the One month.

User Image dmeph Posted - 1 day ago

$BDTX any news ? When is (/ was) the scheduled input ?

User Image Night_Owl_Biotech Posted - 1 day ago

$STRO is off 40% the last 7 trading days. This is the largest drop of 25 peer clinical-stage oncology focused bios with market caps between $150 & $650MM (see attachment). STRO's enterprise value (market cap - cash) = -$167MM. STRO is running a potential reg'l trial in certain ovarian cancers not suited for Elahere & has engaged a banker (Lazard) to find a long-term partner. Put simplest, it is worth investors efforts to fully research STRO as, though of course STRO could fail, its risk/reward profile is compelling again (especially if you believe stocks like STRO trade in cycles) Other clinical-stage oncology focused bios trading for well less than cash with near-term pot'l value inflection points/data reads incl $CMPX $ITOS & $ZNTL $BDTX trades slightly higher than cash but expects a Phase 2 data read in certain lung cancers in Q125 (BDTX's therapy was deemed "de-risked" by Piper Sandler after an interim read 2 months ago). This is not investment advice.

User Image nastento Posted - 1 day ago

$BDTX after listening to the conference from today it seems like phase 2 read out for first line therapy may be delayed to q2. They said they learned what ppl want to see from the first phase 2 read out and that's durability over 1 year. They first started dosing in spring of 2024. Bring on those cheap shares🤑

User Image 100K2022 Posted - 2 days ago

$BDTX hope we get some news today from the Stifel Healthcare Conference, we all need some green.

User Image Rickyrickz70 Posted - 3 days ago

$BDTX had to sell off during the sell off but back in This stock is a bargain at sub 3.00$. It will take some time but this company can easily go above the billion market cap with their 4th generation egfr inhibitor

User Image waugusti Posted - 3 days ago

$BDTX 4 institutions are holding 50% of the shares: T. Rowe Price Investment Management, Inc. 18.97% Bellevue Group AG 15.05% Vestal Point Capital, LP 8.89% NEA Management Company, LLC 7.86%

User Image nastento Posted - 3 days ago

$BDTX to give you some perspective osimertinib reported 43% ORR for second line therapy (193 patient population)They are currently best in class for 1st line therapy at 77% ORR https://pmc.ncbi.nlm.nih.gov/articles/PMC10183387/ As seem here:https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:cec46a3b-c53f-4030-8ff2-5bddc0121a89 BDTX-1535 is an effective second line therapy to osimertinib as it treats mutations caused by osimertinib

User Image nastento Posted - 3 days ago

$BDTX if data I'm Q1 for 1st line therapy is in the high 60s+ this will flyyyy. Right now it's competitive for 2L/3L

User Image nastento Posted - 3 days ago

$BDTX phase 2 readout on BDTX-1535 in Q1? Stay under 3 for a few more weeks🙏

User Image stay_ignorant13 Posted - 6 days ago

$BDTX https://www.gurufocus.com/news/2603771/vestal-point-capital-lp-increases-stake-in-black-diamond-therapeutics-inc https://www.gurufocus.com/news/2604442/t-rowe-price-investment-management-inc-expands-stake-in-black-diamond-therapeutics-inc

User Image 100K2022 Posted - 1 week ago

$BDTX anyone averaging down?

User Image stay_ignorant13 Posted - 1 week ago

$BDTX why is this going down ?

User Image 100K2022 Posted - 2 weeks ago

$BDTX I like it!!

User Image Wilder992001 Posted - 2 weeks ago

$BDTX nice

User Image Jasonstk Posted - 2 weeks ago

$BDTX look ! BDTX announced the joining conference 19,November and 4.December Super potential..! Black Diamond Therapeutics to Participate in Upcoming Investor Conferences https://finance.yahoo.com/news/black-diamond-therapeutics-participate-upcoming-120000585.html

User Image 100K2022 Posted - 2 weeks ago

$BDTX earnings tomorrow

User Image waugusti Posted - 10/31/24

$BDTX tax loss selling.

User Image Jafo333isme Posted - 10/31/24

$BDTX that has been brutal

User Image QueenzGamebyte Posted - 10/31/24

$BDTX wait 4 more days till the earnings report hopefully it will start squeezing up

User Image 100K2022 Posted - 10/31/24

$BDTX thinking about pulling the plug, this is ugly

User Image QueenzGamebyte Posted - 10/31/24

$BDTX how come Price Target Maintained With a $16.00/Share by Wedbush is ground rocketing non-stop for over a month? if predictions are proper, eventually should squeeze the shorts, let's see...

User Image TPTradingCo Posted - 10/30/24

$BDTX whew, close one. Bottom is in, now we ride…

User Image Boomer52 Posted - 10/30/24

$BDTX Formed a nice Pincher Play. Expecting this to go above the SMA20.

User Image TheLearnerEarner Posted - 10/30/24

$BDTX ✅ HUGELY UNDERVALUED stock swing trade - healthcare - small cap - 3/9 F-Score - 0.31x relative volume - 1x analyst outperform rating - 5x analyst buy rating - has more assets than liabilities - short term gains (with potential for a medium term upgrade) 💱 RSI: 29.60 (oversold) 📊 Analysts Price Target: $16.00 - $20.00 (445.14% - 582.59% above Price) 🌟 Range (12m) $1.62 - $7.66 💰 NEWSDESK (last recent article) 📰 https://finance.yahoo.com/news/black-diamond-therapeutics-announces-restructuring-200100587.html

Analyst Ratings
HC Wainwright & Co. Buy Sep 24, 24
Piper Sandler Overweight Sep 23, 24
HC Wainwright & Co. Buy Sep 18, 24
Wedbush Outperform Sep 10, 24
HC Wainwright & Co. Buy Sep 4, 24
Wedbush Outperform Aug 7, 24
Raymond James Outperform Jul 31, 24
Piper Sandler Overweight Jul 3, 24
HC Wainwright & Co. Buy Jun 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Behbahani Ali Director Director Jul 05 Buy 5.00 1,000,000 5,000,000 4,448,757 07/06/23
BIOTECH GROWTH N V 10% Owner 10% Owner Jun 27 Buy 5.4914 1,740,000 9,555,036 7,117,839 06/29/23
BIOTECH GROWTH N V 10% Owner 10% Owner Oct 27 Buy 2.03 364,652 740,244 5,278,038 10/31/22
BIOTECH GROWTH N V 10% Owner 10% Owner Apr 18 Buy 3.27 300,000 981,000 4,288,402 04/20/22
BIOTECH GROWTH N V 10% Owner 10% Owner Apr 12 Buy 3.5 252,556 883,946 3,988,402 04/14/22
Hatzis-Schoch Brent See Remarks See Remarks Apr 13 Option 3.2 4,078 13,050 12,478 04/13/21
Hatzis-Schoch Brent See Remarks See Remarks Apr 13 Sell 25 4,078 101,950 8,400 04/13/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Mar 04 Option 10.86 2,500 27,150 5,700 03/04/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Mar 04 Sell 26.21 2,500 65,525 3,200 03/04/21
Hatzis-Schoch Brent See Remarks See Remarks Feb 12 Sell 27.43 4,078 111,860 8,400 02/12/21
Hatzis-Schoch Brent See Remarks See Remarks Feb 12 Option 3.2 4,078 13,050 12,478 02/12/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Feb 04 Option 10.86 2,500 27,150 5,700 02/04/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Feb 04 Sell 25.35 2,500 63,375 3,200 02/04/21
Hatzis-Schoch Brent See Remarks See Remarks Jan 14 Option 7.03 11,578 81,393 19,978 01/14/21
Hatzis-Schoch Brent See Remarks See Remarks Jan 14 Sell 32.49 11,578 376,169 8,400 01/14/21
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Jan 11 Option 10.86 3,000 32,580 3,000 01/11/21
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Jan 11 Sell 33.94 3,000 101,820 01/11/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Jan 06 Option 10.86 2,500 27,150 5,700 01/06/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Jan 06 Sell 31.54 2,500 78,850 3,200 01/06/21
Epstein David M. See Remarks See Remarks Jan 06 Option 6.42 3,000 19,260 708,423 01/06/21
Epstein David M. See Remarks See Remarks Jan 06 Sell 31.39 12,000 376,680 696,423 01/06/21
Bolzon Bradley J PhD Director Director Dec 01 Sell 33.65 10,393 349,724 874,099 12/01/20
Bolzon Bradley J PhD Director Director Nov 23 Sell 33.01 130,017 4,291,861 4,818,600 11/23/20
Bolzon Bradley J PhD Director Director Nov 19 Sell 33.07 4,730 156,421 4,933,454 11/19/20
Bolzon Bradley J PhD Director Director Nov 17 Sell 33.62 4,700 158,014 4,937,632 11/17/20
Bolzon Bradley J PhD Director Director Nov 13 Sell 34.34 15,598 535,635 4,941,784 11/13/20
Bolzon Bradley J PhD Director Director Nov 12 Sell 34.1 39,583 1,349,780 5,646,377 11/12/20
Bolzon Bradley J PhD Director Director Nov 10 Sell 33.09 9,400 311,046 5,681,344 11/10/20
Bolzon Bradley J PhD Director Director Nov 06 Sell 33.14 11,348 376,073 5,689,647 11/06/20
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Nov 04 Option 10.86 2,500 27,150 2,500 11/04/20
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Nov 04 Sell 31.95 2,500 79,875 11/04/20
Epstein David M. See Remarks See Remarks Nov 03 Sell 31.5 12,000 378,000 711,923 11/03/20
Epstein David M. See Remarks See Remarks Nov 03 Option 6.42 3,000 19,260 723,923 11/03/20
Bolzon Bradley J PhD Director Director Oct 28 Sell 33.17 8,903 295,313 5,699,671 10/28/20
Bolzon Bradley J PhD Director Director Oct 20 Sell 33.35 15,746 525,129 5,707,536 10/20/20
Bolzon Bradley J PhD Director Director Oct 15 Sell 33.24 17,240 573,058 5,721,445 10/15/20
Bolzon Bradley J PhD Director Director Oct 13 Sell 33.43 22,625 756,354 5,736,674 10/13/20
Bolzon Bradley J PhD Director Director Oct 08 Sell 33.41 45,926 1,534,388 5,756,660 10/08/20
Hatzis-Schoch Brent See Remarks See Remarks Sep 16 Option 3.2 4,078 13,050 7,078 09/16/20
Hatzis-Schoch Brent See Remarks See Remarks Sep 16 Sell 31.58 4,078 128,783 3,000 09/16/20
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Sep 16 Option 10.86 3,000 32,580 3,000 09/16/20
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Sep 16 Sell 31 3,000 93,000 09/16/20